Heads

  • Jesús Egido de los Ríos (Professor, UAM / Head of Group CIBERDEM)
  • Alberto Ortiz Arduán (Associate Professor UAM / Coordinator REDINREN)
  • Carmen Gómez-Guerrero (Lecturer, UAM)
  • Oscar Lorenzo González (Lecturer, UAM)
  • José Luis Martín Ventura (Lecturer, UAM)
  • Marta Ruiz Ortega (Lecturer UAM, Head of Group REDINREN)
  • Clotilde Vázquez Martínez (Head of Associate Group, CIBEROBN)
  • Luis Blanco Colio (Head of Group RIC)
  • Nieves González GómezFoto personal
  • Juan Antonio Moreno Gutierrez
  • Adrián Mario Ramos Cortassa
  • Ana Belén Sanz Bartolomé
  • Adela Rovira Loscos (Associate Professor, UAM)



Research staff

  • Matilde Alique Aguilar
  • Elena Burillo Ipiens
  • Esther Civantos Martín
  • Carlos Ernesto Fernández García
  • Ana Belén García Redondo
  • Liliana González Espinosa
  • Emilio González-Parra
  • Manuel Jesús Hernández Pérez
  • Concepción Izquierdo Carnero
  • Iolanda Lázaro López
  • Sebastián Mas Fontao
  • Ana María Ramos Verde
  • Maria Encarnación Rodriguez Ortiz
  • Alfonso Rubio Navarro
  • Beatriz Suárez Álvarez
  • Carlos Tarin Cerezo

Trainee staff

  • Emma Raquel Alegre De Montaner
  • Enrique Bosch Panadero
  • Usama Elewa
  • Beatriz Fernández Fernández
  • Mª Valvanera Fernández Laso
  • Cristian González Guerrero
  • Carolina Gracia Iguacel
  • Irene Gutiérrez Rojas
  • Carolina Lavoz Barria
  • Catalina Martín Cleary
  • Zaida Moreno Villegas
  • José Luis Morgado Pascual
  • Carlos Ocaña Salceda
  • Ainhoa Oguiza Bilbao
  • María Vanessa Pérez Gómez
  • Belén Picatoste Botija
  • Jonay Poveda Núñez
  • Elisa Ramírez Bustillo
  • Sandra Rayego Mateos
  • Carlota Recio Cruz
  • Raúl Rodrigues Díez
  • Jorge Enrique Rojas Rivera
  • Laura Rodriguez-Osorio
  • Gabriela Rossello María
  • Olga Ruiz Andrés
  • Cristina Sastre Reyero

Technical staff and assistants

  • Susana Carrasco Navarro
  • Rosario De Nicolás Miguel
  • Pablo González Prados
  • Mercedes Griera Merinod
  • Patricia Llamas Granda
  • Estrella María Martín-Crespo Aznar

Staff research associates

  • Simona Alexandru. Hospital Universitario Rey Juan Carlos
  • Raquel Barba Martín. Hospital Universitario Rey Juan Carlos
  • Alicia García Pérez. Hospital Universitario Infanta Elena
  • Paloma Iglesias Bolaños. Hospital Universitario Rey Juan Carlos
  • Dolores Joya Seijo. Hospital Universitario Rey Juan Carlos
  • Marta Ossorio González. Hospital Universitario Infanta Elena
  • Amalia Paniagua Ruiz. Hospital Universitario Rey Juan Carlos

Main lines of research


Identification of novel therapeutic targets in nephropathies and in accelerated cardiovascular aging in kidney disease.

Alberto Ortiz

Using "omics" approaches we identify new potential mediators of kidney damage and uremia-induced vascular damage, prioritizing molecules for functional analysis of their potential as therapeutic targets in cell and animal models, and studying their potential as biomarkers in cohorts of patients with renal diseases with clear cardiovascular involvement.

*Principal Investigator: Alberto Ortiz Arduan




Molecular mechanisms associated with vascular and kidney damage.

Our research focuses on the study of the molecular and cellular mechanisms associated with vascular remodeling and the progression of renal damage. Specifically, we study the role of molecular regulators of the inflammatory response, intracellular signaling cascades, extracellular matrix degradative proteins, and oxidative stress in these pathologies.

Mecanismos moleculares

Using "omics" technologies we identify new molecules of diagnostic/prognostic value. We then evaluate their therapeutic potential in functional studies in both cellular and animal models.egradative proteins, and oxidative stress in these pathologies.



* Principal Investigators: Carmen Gómez Guerrero, Luis Miguel Blanco Colio y Jose Luis Martín Ventura


Study of new forms of cell death associated with kidney damage: identification of potential biomarkers and therapeutic targets.


Muerte celularIdentification of the factors that promote necroptosis and other forms of cell death in kidney cell cultures and characterization of the underlying pathways through functional studies. In vivo confirmation of the presence of necroptosis in experimental models of renal damage and study of the therapeutic importance of mediators of necroptosis, identified in cell culture, through in vivo functional studies using inhibitors or genetically modified mice. Confirmation of the presence of necroptosis and the expression of mediators in human kidney samples and characterization of noninvasive methods for monitoring kidney necroptosis.


* Principal Investigator: Ana Belén Sanz Bartolomé

Nieves González


Studies linking bombesin receptor subtype 3 (BRS-3) expression in adipose and muscle tissue with obesity and diabetes in animal models with and without alterations in glucose or lipid metabolism, healthy volunteers, and in obese and/or type 2 diabetes patients in whom BRS-3 receptor gene and protein expression is significantly lower in tissues showing altered metabolism. In vitro experiments performed in primary cultures of human myocytes and adipocyte cell lines have demonstrated the insulin-mimetic effects of a synthetic BRS-3 agonist and modification of the structure of the bombesin peptide, pointing to BRS-3 agonism as a tandem therapy for both obesity and diabetes.


Characterization of the effects of hormones and peptides (GLP-1, exendin-4, exendin-9, amylin) in extrapancreatic tissues (liver, fat, bone and muscle), similar to those induced by insulin, in animal models with and without alterations in glucose or lipid metabolism, and in healthy volunteers and obese and/or type 2 diabetes patients.

* Principal Investigator: Nieves González Gómez



Identification of new pathophysiological mechanisms involved in renal and vascular damage associated with the presence of hemoglobin


Juan Antonio

The aim of our group is to characterize new mechanisms involved in the development of vascular and renal diseases, especially those associated with inflammatory processes and induced by the presence of hemoglobin. We use different cellular and molecular biology techniques in various experimental animal models, cell lines and patient samples, in which we also validate the potential of the aforementioned mediators as diagnostic and/or therapeutic targets.


* Principal Investigator: Juan Antonio Moreno Gutiérrez


Investigation of the molecular mechanisms involved in the process of fibrosis in hypertension-associated renal and cardiovascular diseases.

Our translational objective is to identify new mediators and/or therapeutic targets. We perform basic and preclinical research on renal and cardiovascular diseases, with a particular focus on the renin-angiotensin system and the use of new therapeutic strategies. We currently have several active lines of research. Of note is our study of new mediators of cardio-renal damage, CCN2 and gremlin, which are of potential diagnostic relevance and may constitute therapeutic targets. Our studies of intracellular mechanisms investigate the activation of various pathways, including EGFR, Smad, NF-KB, and redox processes. Finally, we are investigating the role of the Th17 immune response in renal and vascular fibrosis and the effect on these pathologies of blocking the effector cytokine IL-17A.

* Principal Investigator: Marta Ruíz Ortega


Nefrotoxicidad

Nephrotoxicity of drugs for clinical use

We study the renal and extrarenal toxicity of immunosuppressants used to prevent graft rejection, especially calcineurin inhibitors, in cell and animal models.




Use of newly developed nanomedicines for the treatment of experimental renal disease.

We study the molecular basis of the protective effects of polymeric nanoconjugate inhibitors of Apaf-1 and neutralized bacterial endotoxins against apoptosis, inflammation, and fibrosis induced by nephrotoxic agents (drugs, cytokines, and pathogens).


* Principal Investigator: Adrian M. Ramos (Researcher, Miguel Servet Program, ISCIII)


Publications (2014)


Total number of Publications

Nº of Publications with IF

Accumulated IF

Average

IF

Nº of Publications (Q1)

(%) Q1

97

90

451,84

5,02

50

55,56%


1. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Gonzalez-Espinoza L, Ucero AC, Poveda J, Ruiz-Andres O, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A.Macrophages and recently identified forms of cell death.Int Rev Immunol. 2014 Jan;33(1):9-22. doi: 10.3109/08830185.2013.771183. Epub 2013 Jun 26. Review..PubMed PMID:23802146


2. Liabeuf Sophie Okazaki Hirokazu Desjardins Lucie Fliser Danilo Goldsmith David Covic Adrian Wiecek Andrzej Ortiz Alberto Martinez-Castelao Alberto Lindholm Bengt Suleymanlar Gultekin Mallamaci Francesca Zoccali Carmine London Gerard Massy Ziad A .Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?Nephrol Dial Transplant. 2014 Jul;29(7):1275-84. doi: 10.1093/ndt/gft368. Epub 2013 Sep 5. Review..PubMed PMID:24009287


3. López-Oliva MO, Rivas B, Pérez-Fernández E, Ossorio M, Ros S, Chica C, Aguilar A, Bajo MA, Escuin F, Hidalgo L, Selgas R, Jiménez C.Pretransplant peritoneal dialysis relative to hemodialysis improves long-term survival of kidney transplant patients: a single-center observational study.Int Urol Nephrol. 2014 Apr;46(4):825-32. doi: 10.1007/s11255-013-0521-0. Epub 2013 Sep 8..PubMed PMID:24014131


4. Posada-Ayala M, Zubiri I, Martin-Lorenzo M, Sanz-Maroto A, Molero D, Gonzalez-Calero L, Fernandez-Fernandez B, de la Cuesta F, Laborde CM, Barderas MG, Ortiz A, Vivanco F, Alvarez-Llamas G.Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease.Kidney Int. 2014 Jan;85(1):103-11. doi: 10.1038/ki.2013.328. Epub 2013 Sep 18..PubMed PMID:24048377


5. Ucero AC, Benito-Martin A, Izquierdo MC, Sanchez-Niño MD, Sanz AB, Ramos AM, Berzal S, Ruiz-Ortega M, Egido J, Ortiz A.Unilateral ureteral obstruction: beyond obstruction.Int Urol Nephrol. 2014 Apr;46(4):765-76. doi: 10.1007/s11255-013-0520-1. Epub 2013 Sep 27. Review..PubMed PMID:24072452


6. Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM.Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry.Nephrol Dial Transplant. 2014 Feb;29(2):232-9. doi: 10.1093/ndt/gft309. Epub 2013 Sep 30. Review..PubMed PMID:24084326


7. Poveda J, Sanchez-Niño MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A.p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells.Nephrol Dial Transplant. 2014 Jan;29(1):56-64. doi: 10.1093/ndt/gft367. Epub 2013 Oct 28..PubMed PMID:24166466


8. Ruiz-Irastorza G1, Danza A, Perales I, Villar I, Garcia M, Delgado S, Khamashta M..Prednisone in lupus nephritis: how much is enough?Autoimmun Rev. 2014 Feb;13(2):206-14. doi: 10.1016/j.autrev.2013.10.013. Epub 2013 Nov 2..PubMed PMID:24189280


9. Zubiri I, Posada-Ayala M, Sanz-Maroto A, Calvo E, Martin-Lorenzo M, Gonzalez-Calero L, de la Cuesta F, Lopez JA, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G.Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis.J Proteomics. 2014 Jan 16;96:92-102. doi: 10.1016/j.jprot.2013.10.037. Epub 2013 Nov 7..PubMed PMID:24211404


10. Ruiz-Ortega M, Ortiz A, Ramos AM.Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease.Curr Opin Nephrol Hypertens. 2014 Jan;23(1):93-100. doi: 10.1097/01.mnh.0000437331.23794.81. Review..PubMed PMID:24257157


11. Benito-Martin A, Ucero AC, Izquierdo MC, Santamaria B, Picatoste B, Carrasco S, Lorenzo O, Ruiz-Ortega M, Egido J, Ortiz A.Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells.Biochim Biophys Acta. 2014 Feb;1842(2):293-303. doi: 10.1016/j.bbadis.2013.11.022. Epub 2013 Nov 25..PubMed PMID:24287278


12. Tuñón José Blanco-Colio Luis Cristóbal Carmen Tarín Nieves Higueras Javier Huelmos Ana Alonso Joaquín Egido Jesús Asensio Dolores Lorenzo Oscar Mahíllo-Fernández Ignacio Rodríguez-Artalejo Fernando Farré Jerónimo Martín-Ventura José Luis López-Bescós Lorenzo .Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.Am J Cardiol. 2014 Feb 1;113(3):434-40. doi: 10.1016/j.amjcard.2013.10.012. Epub 2013 Nov 7..PubMed PMID:24295549


13. Picatoste B, Ramírez E, Caro-Vadillo A, Iborra C, Ares-Carrasco S, Egido J, Tuñón J, Lorenzo O.Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.PLoS One. 2013;8(10):e78330. doi: 10.1371/journal.pone.0078330. Erratum in: PLoS One. 2014;9(2):e91601. PLoS One. 2013;8(11). doi:10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287. Ares-Carrasco, Sara [added]. .PubMed PMID:24302978


14. Manrique Franco K, Cedeño Díaz Oderay M, Aragón Valera C, Sánchez-Vilar Burdiel O, Rovira Loscos A.Papillary thyroid carcinoma associated to squamous cell carcinoma.Endocrinol Nutr. 2014 Apr;61(4):226-8. doi: 10.1016/j.endonu.2013.10.007. Epub 2013 Dec 12. English, Spanish. .PubMed PMID:24332292


15. Sanchez-Niño Maria Dolores Poveda Jonay Sanz Ana Belen Carrasco Susana Ruiz-Ortega Marta Selgas Rafael Egido Jesus Ortiz Alberto .3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes.Arch Toxicol. 2014 Mar;88(3):597-608. doi: 10.1007/s00204-013-1181-7. Epub 2013 Dec 15..PubMed PMID:24337777


16. Alique M, Civantos E, Sanchez-Lopez E, Lavoz C, Rayego-Mateos S, Rodrigues-Díez R, García-Redondo AB, Egido J, Ortiz A, Rodríguez-Puyol D, Rodríguez-Puyol M, Ruiz-Ortega M.Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation.Clin Sci (Lond). 2014 Jul;127(1):19-31. doi: 10.1042/CS20130412..PubMed PMID:24383472


17. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ.Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.Int J Cardiol. 2014 Feb 15;171(3):309-25. doi: 10.1016/j.ijcard.2013.11.025. Epub 2013 Nov 20. Review..PubMed PMID:24418289


18. Arrieta Francisco Rubio-Terrés Carlos Rubio-Rodríguez Darío Magaña Ana Piñera Marbella Iglesias Pedro Nogales Pedro Calañas Alfonso Novella Blanca Botella-Carretero José Ignacio Debán Carlos Zamarrón Isabel Mora Gustavo Balsa José Antonio Vázquez Clotilde .Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain).Endocrinol Nutr. 2014 Apr;61(4):193-201. doi: 10.1016/j.endonu.2013.11.005. Epub 2014 Jan 17. English, Spanish. .PubMed PMID:24440211


19. Vázquez C Botella-Carretero J I Corella D Fiol M Lage M Lurbe E Richart C Fernández-Real J M Fuentes F Ordóñez A de Cos A I Salas-Salvadó J Burguera B Estruch R Ros E Pastor O Casanueva F F .White fish reduces cardiovascular risk factors in patients with metabolic syndrome: the WISH-CARE study, a multicenter randomized clinical trial.Nutr Metab Cardiovasc Dis. 2014 Mar;24(3):328-35. doi: 10.1016/j.numecd.2013.09.018. Epub 2013 Nov 1..PubMed PMID:24462043


20. Blanco-Colio Luis M .TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.Front Immunol. 2014;5:3. doi: 10.3389/fimmu.2014.00003. Review..PubMed PMID:24478772


21. Sastre Cristina Fernández-Laso Valvanera Madrigal-Matute Julio Muñoz-García Begoña Moreno Juan A Pastor-Vargas Carlos Llamas-Granda Patricia Burkly Linda C Egido Jesús Martín-Ventura Jose L Blanco-Colio Luis M .Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.J Cell Mol Med. 2014 Apr;18(4):721-34. doi: 10.1111/jcmm.12221. Epub 2014 Jan 30..PubMed PMID:24479820


22. Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A.TWEAK and the progression of renal disease: clinical translation.Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i54-i62. doi: 10.1093/ndt/gft342. Review..PubMed PMID:24493870


23. García F B Sanchez I Arrieta F Calañas A Botella-Carretero J I Zamarron I Vázquez C .[Short bowel syndrome cause of hypomagnesaemia importance of its diagnosis and treatment].Nutr Hosp. 2014 Feb 1;29(2):456-9. doi: 10.3305/nh.2014.29.2.7048. Spanish. .PubMed PMID:24528368


24. Moreno Juan Antonio Moreno Sara Rubio-Navarro Alfonso Gómez-Guerrero Carmen Ortiz Alberto Egido Jesús .Role of chemokines in proteinuric kidney disorders.Expert Rev Mol Med. 2014 Feb 17;16:e3. doi: 10.1017/erm.2014.3. Review..PubMed PMID:24534600


25. Rodrigues-Díez R, Aroeira LS, Orejudo M, Bajo MA, Heffernan JJ, Rodrigues-Díez RR, Rayego-Mateos S, Ortiz A, Gonzalez-Mateo G, López-Cabrera M, Selgas R, Egido J, Ruiz-Ortega M.IL-17A is a novel player in dialysis-induced peritoneal damage.Kidney Int. 2014 Aug;86(2):303-15. doi: 10.1038/ki.2014.33. Epub 2014 Feb 19..PubMed PMID:24552849


26. De Sousa-Amorim E, Del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F, Bellon T, Selgas R..Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.Perit Dial Int. 2014 Sep-Oct;34(6):582-93. doi: 10.3747/pdi.2012.00286. Epub 2014 Mar 1..PubMed PMID:24584614


27. Betriu A, Martinez-Alonso M, Arcidiacono MV, Cannata-Andia J, Pascual J, Valdivielso JM, Fernández E.Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study.Nephrol Dial Transplant. 2014 Jul;29(7):1415-22. doi: 10.1093/ndt/gfu038. Epub 2014 Feb 28..PubMed PMID:24586070


28. Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Nephrol Dial Transplant. 2014 Aug;29(8):1563-70. doi: 10.1093/ndt/gfu039. Epub 2014 Mar 2..PubMed PMID:24589724


29. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.PLoS One. 2014;9(3):e90541. doi: 10.1371/journal.pone.0090541..PubMed PMID:24594990


30. Sanz AB, Aroeira LS, Bellon T, del Peso G, Jimenez-Heffernan J, Santamaria B, Sanchez-Niño MD, Blanco-Colio LM, Lopez-Cabrera M, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A.TWEAK promotes peritoneal inflammation.PLoS One. 2014;9(3):e90399. doi: 10.1371/journal.pone.0090399..PubMed PMID:24599047


31. Martinez-Pinna R, Lindholt JS, Madrigal-Matute J, Blanco-Colio LM, Esteban-Salan M, Torres-Fonseca MM, Lefebvre T, Delbosc S, Laustsen J, Driss F, Vega de Ceniga M, Gouya L, Weiss G, Egido J, Meilhac O, Michel JB, Martin-Ventura JL.From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm.Thromb Haemost. 2014 Jul 3;112(1):87-95. doi: 10.1160/TH13-08-0721. Epub 2014 Mar 6..PubMed PMID:24599423


32. González-Parra E, Egido J.[Vitamin D, metabolic syndrome and diabetes mellitus].Med Clin (Barc). 2014 Jun 6;142(11):493-6. doi: 10.1016/j.medcli.2014.01.024. Epub 2014 Mar 13. Spanish. .PubMed PMID:24629694


33. Vega de Ceniga M, Esteban M, Barba A, Estallo L, Blanco-Colio LM, Martin-Ventura JL.Assessment of biomarkers and predictive model for short-term prospective abdominal aortic aneurysm growth-A pilot study.Ann Vasc Surg. 2014 Oct;28(7):1642-8. doi: 10.1016/j.avsg.2014.02.025. Epub 2014 Mar 12..PubMed PMID:24632318


34. Zapatero A, Gómez-Huelgas R, González N, Canora J, Asenjo A, Hinojosa J, Plaza S, Marco J, Barba R..Frequency of hypoglycemia and its impact on length of stay, mortality, and short-term readmission in patients with diabetes hospitalized in internal medicine wards.Endocr Pract. 2014 Sep;20(9):870-5. doi: 10.4158/EP14006.OR..PubMed PMID:24641928


35. Arce JM, Hernando L, Ortiz A, Díaz M, Polo M, Lombardo M, Robles A.Designing a method to assess and improve the quality of healthcare in Nephrology by means of the Delphi technique.Nefrologia. 2014;34(2):158-74. doi: 10.3265/Nefrologia.pre2013.Dec.12286. English, Spanish. .PubMed PMID:24658191


36. Calderón Berniza Galdón Alba Calañas Alfonso Peromingo Roberto Galindo Julio García-Moreno Francisca Rodriguez-Velasco Gloria Martín-Hidalgo Antonia Vazquez Clotilde Escobar-Morreale Héctor F Botella-Carretero José I .Effects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive procedures.Obes Surg. 2014 Oct;24(10):1686-92. doi: 10.1007/s11695-014-1233-y..PubMed PMID:24664512


37. Culebras JM.[Neurological changes related to malnutrition during the spanish civil war (1936-1939)].Nutr Hosp. 2014 Apr 1;29(4):712-8. doi: 10.3305/nh.2014.29.4.7346. Spanish. .PubMed PMID:24679012


38. Serra-Majem L, Riobó Serván P, Belmonte Cortés S, Anadón Navarro A, Aranceta Bartrina J, Franco Vargas E, García-Closas R, Gómez-Candela C, Herrero Sancho E, La Vecchia C, López Díaz-Ufano ML, Varela-Moreiras G, Vázquez Castro J, Ribas-Barba L, Alcaraz-Cebrián F, García-Luna PP, González-Gomis M, González-Gross M, Granado de la Orden S, López-Sobaler AM, Moreno Villares JM, Ortega Anta RM, Pérez-Rodrigo C, Polanco Allué I, Urrialde de Andrés R.Chinchón declaration; decalogue on low- and no-calorie sweeteners (LNCS).Nutr Hosp. 2014 Apr 1;29(4):719-34. doi: 10.3305/nh.2014.29.4.7393..PubMed PMID:24679013


39. Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noé B.Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages.Atherosclerosis. 2014 Jun;234(2):311-9. doi: 10.1016/j.atherosclerosis.2014.03.020. Epub 2014 Mar 27. Review..PubMed PMID:24726899


40. Ramírez CM, Lin CS, Abdelmohsen K, Goedeke L, Yoon JH, Madrigal-Matute J, Martin-Ventura JL, Vo DT, Uren PJ, Penalva LO, Gorospe M, Fernández-Hernando C.RNA binding protein HuR regulates the expression of ABCA1.J Lipid Res. 2014 Apr 11;55(6):1066-1076. [Epub ahead of print].PubMed PMID:24729624


41. Fuentes-Antrás J, Ioan AM, Tuñón J, Egido J, Lorenzo O.Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation.Int J Endocrinol. 2014;2014:847827. doi: 10.1155/2014/847827. Epub 2014 Mar 12. Review..PubMed PMID:24744784


42. Tuñón J, Cristóbal C, Tarín N, Aceña A, González-Casaus ML, Huelmos A, Alonso J, Lorenzo O, González-Parra E, Mahíllo-Fernández I, Pello AM, Carda R, Farré J, Rodríguez-Artalejo F, López-Bescós L, Egido J.Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.PLoS One. 2014;9(4):e95402. doi: 10.1371/journal.pone.0095402..PubMed PMID:24748388


43. Montañez-Barragán A, Gómez-Barrera I, Sanchez-Niño MD, Ucero AC, González-Espinoza L, Ortiz A.Osteoprotegerin and kidney disease.J Nephrol. 2014 Apr 23. [Epub ahead of print].PubMed PMID:24756971


44. Alvarez-Llamas G, Vivanco F, Ortiz A.The authors reply:.Kidney Int. 2014 May;85(5):1240. doi: 10.1038/ki.2014.39. .PubMed PMID:24786881


45. Moreno JA, Ortega-Gomez A, Rubio-Navarro A, Louedec L, Ho-Tin-Noé B, Caligiuri G, Nicoletti A, Levoye A, Plantier L, Meilhac O.High-density lipoproteins potentiate α1-antitrypsin therapy in elastase-induced pulmonary emphysema.Am J Respir Cell Mol Biol. 2014 Oct;51(4):536-49. doi: 10.1165/rcmb.2013-0103OC..PubMed PMID:24787644


46. Lavoz Carolina Droguett Alejandra Burgos M Eugenia Carpio Daniel J Ortiz Alberto Egido Jesús Mezzano Sergio Ruiz-Ortega Marta .Translational study of the Notch pathway in hypertensive nephropathy.Nefrologia. 2014 May 21;34(3):369-76. doi: 10.3265/Nefrologia.pre2014.Jan.12436. Epub 2014 Apr 30. English, Spanish. .PubMed PMID:24798563


47. Fernandez-Fernandez Beatriz Ortiz Alberto Gomez-Guerrero Carmen Egido Jesus .Therapeutic approaches to diabetic nephropathy--beyond the RAS.Nat Rev Nephrol. 2014 Jun;10(6):325-46. doi: 10.1038/nrneph.2014.74. Epub 2014 May 6. Review..PubMed PMID:24802062


48. Rodriguez-Osorio L, Fernandez-Fernandez B, Martin-Cleary C, Ortiz A.Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis.J Postgrad Med. 2014 Apr-Jun;60(2):200-1. doi: 10.4103/0022-3859.132348..PubMed PMID:24823525


49. Arrieta F, Balsa JA, de la Puerta C, Botella JI, Zamarrón I, Elías E, Río JI, Alonso P, Candela A, Blanco-Colio LM, Egido J, Navarro P, Vázquez C.Phase IV prospective clinical study to evaluate the effect of taurine on liver function in postsurgical adult patients requiring parenteral nutrition.Nutr Clin Pract. 2014 Oct;29(5):672-80. doi: 10.1177/0884533614533610. Epub 2014 May 14..PubMed PMID:24829298


50. García B F Peromingo R Galindo J Arrieta F Sánchez J Vázquez C Botella-Carretero J I .Case report subtotal pancreatectomy as treatment for severe hypoglycemia after gastric bypass.Endocrinol Nutr. 2014 Aug-Sep;61(7):391-3. doi: 10.1016/j.endonu.2014.04.001. Epub 2014 May 16. English, Spanish. .PubMed PMID:24837353


51. Nastou D, Fernández-Fernández B, Elewa U, González-Espinoza L, González-Parra E, Sanchez-Niño MD, Ortiz A.Next-generation phosphate binders: focus on iron-based binders.Drugs. 2014 Jun;74(8):863-77. doi: 10.1007/s40265-014-0224-6..PubMed PMID:24848754


52. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM, Board of the EURECA-m Working Group of ERA-EDTA.Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure.Lancet. 2014 May 24;383(9931):1831-43. doi: 10.1016/S0140-6736(14)60384-6. Review..PubMed PMID:24856028


53. Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD, Carrero JJ, Ortiz A.CXCL16 in kidney and cardiovascular injury.Cytokine Growth Factor Rev. 2014 Jun;25(3):317-25. doi: 10.1016/j.cytogfr.2014.04.002. Epub 2014 May 2. Review..PubMed PMID:24861945


54. Martín P, Mora I, Cortes MA, Calleros L, García-Jerez A, Ortiz A, Rodríguez-Puyol M, Rodríguez-Puyol D, Olmos G.Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis.Am J Physiol Renal Physiol. 2014 Jul 1;307(1):F75-85. doi: 10.1152/ajprenal.00398.2013. Epub 2014 May 28..PubMed PMID:24872318


55. Martinez-Pinna Roxana Gonzalez de Peredo Anne Monsarrat Bernard Burlet-Schiltz Odile Martin-Ventura Jose Luis .Label-free quantitative proteomic analysis of human plasma-derived microvesicles to find protein signatures of abdominal aortic aneurysms.Proteomics Clin Appl. 2014 Aug;8(7-8):620-5. doi: 10.1002/prca.201400010..PubMed PMID:24888668


56. Sanchez-Niño MD, Ortiz A.'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.Nephrol Dial Transplant. 2015 Mar;30(3):394-400. Epub 2014 Jun 9. Review..PubMed PMID:24914092


57. Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz C, Carvajal G, Droguett A, Garcia-Redondo AB, Rodriguez I, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M.Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells.Biomed Res Int. 2014;2014:802841. doi: 10.1155/2014/802841. Epub 2014 May 18..PubMed PMID:24949470


58. Martinez-Pinna R, Burillo E, Madrigal-Matute J, Lopez JA, Camafeita E, Torres-Fonseca MM, Llamas-Granda P, Egido J, Michel JB, Miguel Blanco-Colio L, Martin-Ventura JL.Label-free proteomic analysis of red blood cell membrane fractions from abdominal aortic aneurysm patients.Proteomics Clin Appl. 2014 Aug;8(7-8):626-30. doi: 10.1002/prca.201400035..PubMed PMID:24976601


59. Gallegos-Villalobos A, Portolés J, Ortiz A.Application of the new cholesterol guidelines.N Engl J Med. 2014 Jul 3;371(1):77-8. doi: 10.1056/NEJMc1405680#SA1. .PubMed PMID:24988563


60. Vegas-Sánchez MC, Rollán-Landeras E, García-Rodríguez JJ, Bolás-Fernández F.Induction of ulcerative colitis in mice influences the course of infection with the nematode Trichuris muris.J Helminthol. 2014 Jul 9:1-8. [Epub ahead of print].PubMed PMID:25007240


61. Recio Carlota Oguiza Ainhoa Lazaro Iolanda Mallavia Beñat Egido Jesus Gomez-Guerrero Carmen .Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1953-60. doi: 10.1161/ATVBAHA.114.304144. Epub 2014 Jul 10..PubMed PMID:25012131


62. Fernández-Laso V, Sastre C, Egido J, Martín-Ventura JL, Blanco-Colio LM.[Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].Clin Investig Arterioscler. 2015 Jan-Feb;27(1):17-25. doi: 10.1016/j.arteri.2014.04.003. Epub 2014 Jul 12. Spanish. .PubMed PMID:25027757


63. Gracia-Iguacel Carolina González-Parra Emilio Barril-Cuadrado Guillermina Sánchez Rosa Egido Jesús Ortiz-Arduán Alberto Carrero Juan J .Defining protein-energy wasting syndrome in chronic kidney disease: prevalence and clinical implications.Nefrologia. 2014;34(4):507-19. doi: 10.3265/Nefrologia.pre2014.Apr.12522. English, Spanish. .PubMed PMID:25036065


64. Droguett Alejandra Krall Paola Burgos M Eugenia Valderrama Graciela Carpio Daniel Ardiles Leopoldo Rodriguez-Diez Raquel Kerr Bredford Walz Katherina Ruiz-Ortega Marta Egido Jesus Mezzano Sergio .Tubular overexpression of gremlin induces renal damage susceptibility in mice.PLoS One. 2014;9(7):e101879. doi: 10.1371/journal.pone.0101879..PubMed PMID:25036148


65. Cortés M Alicia Irrazábal Emanuel García-Jerez Andrea Bohórquez-Magro Lourdes Luengo Alicia Ortiz-Arduán Alberto Calleros Laura Rodríguez-Puyol Manuel .Impact of implementing ISO 9001:2008 standard on the Spanish Renal Research Network biobank sample transfer process.Nefrologia. 2014 Sep 26;34(5):552-60. doi: 10.3265/Nefrologia.pre2014.Apr.12292. Epub 2014 May 30. English, Spanish. .PubMed PMID:25036260


66. Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Niño MD, Villarrubia J, Ortiz A.Deferasirox nephrotoxicity-the knowns and unknowns.Nat Rev Nephrol. 2014 Oct;10(10):574-86. doi: 10.1038/nrneph.2014.121. Epub 2014 Jul 22..PubMed PMID:25048549


67. Baragaño Raneros A, Suarez-Álvarez B, López-Larrea C.Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.Oncoimmunology. 2014;3:e28497. Review..PubMed PMID:25050215


68. Rodrigues-Diez RR, Garcia-Redondo AB, Orejudo M, Rodrigues-Diez R, Briones AM, Bosch-Panadero E, Kery G, Pato J, Salaices M, Ortiz A, Egido J, Ruiz-Ortega M.The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells.Antioxid Redox Signal. 2015 Jan 1;22(1):29-47. doi: 10.1089/ars.2013.5500..PubMed PMID:25065408


69. Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E.Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.Am J Transl Res. 2014;6(4):340-52. Review..PubMed PMID:25075251


70. Tarín C, Fernández-Laso V, Sastre C, Madrigal-Matute J, Gómez M, Zaragoza C, Egido J, Burkly LC, Martín-Ventura JL, Blanco-Colio LM.Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice.J Am Heart Assoc. 2014 Aug 4;3(4). doi:pii: e000723. 10.1161/JAHA.113.000723. Erratum in: J Am Heart Assoc. 2014 Oct;3(5):000509. .PubMed PMID:25092786


71. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, Beloqui O, Llamas-Granda P, Ortiz A, Egido J, Blanco-Colio LM, Martin-Ventura JL.Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.J Am Heart Assoc. 2014 Aug 5;3(4). doi:pii: e000785. 10.1161/JAHA.114.000785..PubMed PMID:25095870


72. Tábara LC, Poveda J, Martin-Cleary C, Selgas R, Ortiz A, Sanchez-Niño MD.Mitochondria-targeted therapies for acute kidney injury.Expert Rev Mol Med. 2014 Aug 8;16:e13. doi: 10.1017/erm.2014.14. Review. Erratum in: Expert Rev Mol Med. 2014;16:e14. .PubMed PMID:25104110


73. Higueras J, Martín-Ventura JL, Blanco-Colio L, Cristóbal C, Tarín N, Huelmos A, Alonso J, Pello A, Aceña A, Carda R, Lorenzo O, Mahíllo-Fernández I, Asensio D, Almeida P, Rodríguez-Artalejo F, Farré J, López Bescós L, Egido J, Tuñón J.[Impact of plasma pro-B-type natriuretic peptide amino-terminal and galectin-3 levels on the predictive capacity of the LIPID Clinical Risk Scale in stable coronary disease].Clin Investig Arterioscler. 2015 Mar-Apr;27(2):57-63. doi: 10.1016/j.arteri.2014.06.003. Epub 2014 Aug 13. Spanish. .PubMed PMID:25127747


74. Olveira G, Tapia MJ, Ocón J, Cabrejas-Gómez C, Ballesteros-Pomar MD, Vidal-Casariego A, Arraiza-Irigoyen C, Olivares J, Conde-García MC, García-Manzanares A, Botella-Romero F, Quílez-Toboso RP, Cabrerizo L, Matía P, Chicharro L, Burgos R, Pujante P, Ferrer M, Zugasti A, Petrina E, Manjón L, Diéguez M, Carrera MJ, Vila-Bundo A, Urgelés JR, Aragón-Valera C, Sánchez-Vilar O, Bretón I, García-Peris P, Muñoz-Garach A, Márquez E, Del Olmo D, Pereira JL, Tous MC.Prevalence of diabetes, prediabetes, and stress hyperglycemia: insulin therapy and metabolic control in patients on total parenteral nutrition (prospective multicenter study).Endocr Pract. 2015 Jan;21(1):59-67. doi: 10.4158/EP13441.OR..PubMed PMID:25148810


75. Ars Elisabet Bernis Carmen Fraga Gloria Martínez Víctor Martins Judith Ortiz Alberto Rodríguez-Pérez José Carlos Sans Laia Torra Roser .Spanish guidelines for the management of autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv95-105. doi: 10.1093/ndt/gfu186..PubMed PMID:25165191


76. Pérez-Rial Sandra Del Puerto-Nevado Laura Girón-Martínez Alvaro Terrón-Expósito Raúl Díaz-Gil Juan J González-Mangado Nicolás Peces-Barba Germán .Liver growth factor treatment reverses emphysema previously established in a cigarette smoke exposure mouse model.Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1;307(9):L718-26. doi: 10.1152/ajplung.00293.2013. Epub 2014 Aug 29..PubMed PMID:25172913


77. van der Tol Linda Svarstad Einar Ortiz Alberto Tøndel Camilla Oliveira João Paulo Vogt Liffert Waldek Stephen Hughes Derralynn A Lachmann Robin H Terryn Wim Hollak Carla E Florquin Sandrine van den Bergh Weerman Marius A Wanner Christoph West Michael L Biegstraaten Marieke Linthorst Gabor E .Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.Mol Genet Metab. 2015 Feb;114(2):242-7. doi: 10.1016/j.ymgme.2014.08.007. Epub 2014 Aug 20..PubMed PMID:25187469


78. Lorenzo-Almorós Ana Polo-Sabau Jorge Barrio-Dorado María Del Pilar Ruggiero García María .[Acute liver injury induced by green tea extracts].Gastroenterol Hepatol. 2015 Jan;38(1):44-5. doi: 10.1016/j.gastrohep.2014.07.004. Epub 2014 Sep 7. Spanish. .PubMed PMID:25205081


79. Gracia-Iguacel Carolina González-Parra Emilio Egido Jesús Lindholm Bengt Mahillo Ignacio Carrero Juan Jesús Ortiz Alberto .Cortisol levels are associated with mortality risk in hemodialysis patients.Clin Nephrol. 2014 Oct;82(4):247-56..PubMed PMID:25216457


80. Buendía Paula Carracedo Julia Soriano Sagrario Madueño Juan Antonio Ortiz Alberto Martín-Malo Alejandro Aljama Pedro Ramírez Rafael .Klotho Prevents NFκB Translocation and Protects Endothelial Cell From Senescence Induced by Uremia.J Gerontol A Biol Sci Med Sci. 2014 Sep 22. doi:pii: glu170. [Epub ahead of print].PubMed PMID:25246106


81. Martín-Navarro Juan A Gutiérrez-Sánchez María J Petkov-Stoyanov Vladimir Ortiz-Arduán Alberto .Rapid progression of polycystic kidney disease during treatment with tumour necrosis factor-neutralising antibodies.Nefrologia. 2014 Sep 26;34(5):681-3. doi: 10.3265/Nefrologia.pre2014.Jun.12600. English, Spanish. .PubMed PMID:25259825


82. Caro Jara Gutiérrez-Solís Elena Rojas-Rivera Jorge Agraz Irene Ramos Natalia Rabasco Cristina Espinosa Mario Valera Alfonso Martín Mónica Frutos Miguel Ángel Perea Lara Juárez Gema Fernández Ocaña Javier Arroyo David Goicoechea Marian Fernández Laura Oliet Aniana Hernández Yolanda Romera Ana Segarra Alfons Praga Manuel, .Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.Nephrol Dial Transplant. 2015 Mar;30(3):467-74. doi: 10.1093/ndt/gfu306. Epub 2014 Oct 1..PubMed PMID:25274748


83. Janeiro Dario Portoles Jose María Tato Ana Lopez-Sanchez Paula Del Peso Gloria Rivera Maite Castellano Ines Fernandez-Reyes M J Perez-Gomez Vanessa Ortega Mayra Martinez-Miguel Patricia Felipe Carmen Caparros Guadalupe Ortiz Alberto Selgas Rafael .PERITONEAL DIALYSIS CAN BE AN OPTION FOR DOMINANT POLYCYSTIC KIDNEY DISEASE: AN OBSERVATIONAL STUDY.Perit Dial Int. 2014 Oct 7. doi:pii: pdi.2014.00029. [Epub ahead of print].PubMed PMID:25292408


84. Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernández E.Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.BMC Nephrol. 2014 Oct 18;15:168. doi: 10.1186/1471-2369-15-168..PubMed PMID:25326683


85. Riobó Serván Pilar Sierra Poyatos Roberto Soldo Rodríguez Judith .Low and no calorie sweeteners (LNCS); myths and realities.Nutr Hosp. 2014 Sep 22;30 Suppl 2e:49-55. doi: 10.3305/nh.2014.30.sup2e.8288..PubMed PMID:25344624


86. Espinosa-Diez Cristina Fierro-Fernandez Marta Sánchez-Gómez Francisco J Rodriguez-Pascual Fernando Alique Matilde Ruiz-Ortega Marta Beraza Naiara Martínez-Chantar Maria Luz Fernandez-Hernando Carlos Lamas Santiago .Targeting of Gamma-Glutamyl-Cysteine Ligase by miR-433 Reduces Glutathione Biosynthesis and Promotes TGF-β-Dependent Fibrogenesis.Antioxid Redox Signal. 2014 Oct 29. [Epub ahead of print].PubMed PMID:25353619


87. Alique Matilde Sánchez-López Elsa Rayego-Mateos Sandra Egido Jesús Ortiz Alberto Ruiz-Ortega Marta .Angiotensin II, via angiotensin receptor type 1/nuclear factor-κB activation, causes a synergistic effect on interleukin-1-β-induced inflammatory responses in cultured mesangial cells.J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):23-32. doi: 10.1177/1470320314551564. Epub 2014 Oct 29..PubMed PMID:25354522


88. Fernandez-Fernandez Beatriz Martin-Cleary Catalina Ortiz Alberto.Bicarbonate therapy, phosphate binders, and risk for vascular calcification.Kidney Int. 2014 Nov;86(5):1056. doi: 10.1038/ki.2014.191. .PubMed PMID:25360495


89. Pérez-Miguelsanz María Juliana Herrera-Hervás Luis Franco-López María de Los Ángeles.[Fast visualization of fat infiltration in dorsal muscles of the trunk at lumbar spinal column by magnetic resonance images (MR)].Nutr Hosp. 2014 Nov 1;30(5):1160-4. doi: 10.3305/nh.2014.30.5.7712. Spanish. .PubMed PMID:25365022


90. Ramos AM. Marazuela M, Paniagua A, et al.Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.Eur J Endocrinol. 2015 Feb;172(2):115-22. doi: 10.1530/EJE-14-0613. Epub 2014 Nov 10..PubMed PMID:25385818


91. Baragaño Raneros A Martín-Palanco V Fernandez A F Rodriguez R M Fraga M F Lopez-Larrea C Suarez-Alvarez B .Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.Genes Immun. 2015 Jan-Feb;16(1):71-82. doi: 10.1038/gene.2014.58. Epub 2014 Nov 13..PubMed PMID:25393931


92. Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cortés M, Gallegos-Villalobos A, Garcia D, García-Robles JA, Egido J, Gutiérrez-Rivas E, Herrero JA, Mas S, Oancea R, Péres P, Salazar-Martín LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP..The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.Mol Genet Metab. 2015 Feb;114(2):248-58. doi: 10.1016/j.ymgme.2014.11.004. Epub 2014 Nov 9..PubMed PMID:25468652


93. GBD 2013 Mortality and Causes of Death Collaborators (A Ortiz incluido).Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18..PubMed PMID:25530442


94. Gonzalez-Parra E, Gonzalez-Casaus ML, Arenas MD, Sainz-Prestel V, Gonzalez-Espinoza L, Muñoz-Rodriguez MA, Tabikh A, Egido J, Ortiz A.Individualization of dialysate calcium concentration according to baseline pre-dialysis serum calcium.Blood Purif. 2014;38(3-4):224-33. doi: 10.1159/000366126. Epub 2014 Dec 19..PubMed PMID:25531119


95. Pello AM, Cristóbal C, Tarín N, Huelmos A, Aceña Á, Carda R, González-Casaus ML, Alonso J, Lorenzo Ó, Blanco-Colio L, Martín-Ventura JL, Franco Peláez JA, Mahíllo-Fernández I, Farré J, López-Bescós L, Egido J, Tuñón J.Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors.J Cardiol. 2014 Dec 19. doi:pii: S0914-5087(14)00334-7. 10.1016/j.jjcc.2014.11.006. [Epub ahead of print].PubMed PMID:25533425


96. Berzal S, González-Guerrero C, Rayego-Mateos S, Ucero Á, Ocaña C, Egido J, Ortiz A, Ruiz-Ortega M, Ramos AM.TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-κB pathway and ERK activation.J Cell Physiol. 2015 Jul;230(7):1580-93. doi: 10.1002/jcp.24905..PubMed PMID:25536182


97. Ruiz-Ortega M, Ortiz A, Ramos AM.Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney diseaseCurrent Opinion in Nephrology and Hypertension2014.PubMed PMID:0


Projects (2013)


1. "TWEAK Y FN 14, Implicaciones básicas y clínicas de su modulación en aterotrombosis" Investigador Principal Dr. L. M Blanco Colio.

Proyecto Público Competitivo PI10/00234.

2. "Implicación de TWEAK (Tumor necrosis factor-like weak inducer of apoptosis) en el desarrollo de la lesión aterosclerótica y/o aneurismal". Investigador Principal Dr. L. M Blanco Colio.

Financiación privada 5280/002.


3. "TWEAK (Tumor necrosis factor-like weak inducer of apoptosis) una nueva proteína implicada en el desarrollo de la lesión aterosclerótica y/o aneurismal". Investigador Principal Dr. L. M Blanco Colio.

Financiación privada 5280/003.


4. "E-PREDICE". Investigador Principal Dr. Jesús Egido de los Ríos.

Proyecto Público Competitivo 20170/007


5. "Identificación de nuevos biomarcadores diagnósticos y estrategias terapéuticas en la enfermedad renal" Investigador Principal Dr. Jesús Egido de los Ríos.

Proyecto Público Competitivo PI10/00072


6. "Red Cardiovascular". Dr. L. M Blanco Colio.

Proyecto Público Competitivo RD12/0042/0038


7. "Grupo de Investigación del CIBER de Diabetes" Investigador Principal Dr. Jesús Egido de los Ríos.

Proyecto Público Competitivo CIBEREDEM.


8. "Mecanismos de progresión del daño renal y vascular en la diabetes: Inmunoinflamación, estrés oxidativo y senescencia celular". Investigadora Principal Dra. C Gómez Guerrero.

Proyecto Público Competitivo SAF2012-38830.


9. "Estudio sobre el papel de receptor Bombesina subtipo-3 en el tejido adiposo humano: uso potencial como diana terapéutica en obesidad y diabetes". Investigadora Principal Dra. N. González Gómez.

Financiación Privada 12224/002.


10. "Estudio de la interrelación entre el factor de transcripción NRf2 y la autofagia en la progresión de la lesión aterosclerótica asociada a la diabetes". ". Investigadora Principal Dra. I. Lázaro López.

Financiación Privada 16676/001.


11. "Role of CD163 in vascular and renal damage". Investigador Principal Dr. J.A. Moreno Gutiérrez.

Proyecto Público Competitivo CP10/00479.


12. "PRIORITY". Investigador Principal Dr. A. Ortiz Arduán.

Proyecto Público Competitivo 279277/PRIORITY.


13. "Caracterización de nuevos mediadores y marcadores de daño renal identificados mediante transcriptómica". Investigador Principal Dr. A. Ortiz Arduán.

Proyecto Público Competitivo PS09/00447.


14. "Red de Investigación Renal (REDinREN)". Investigador Principal Dr. A. Ortiz Arduán.

Proyecto Público Competitivo RD12/0021/0001.


15. "Utilización de modelos animales y celulares para caracterizar el fracaso renal agudo y multiorgánico. CIFRA". Investigador Principal Dr. A. Ortiz Arduán.

Proyecto Público Competitivo S2010/BMD-2378 CIFRA.


16. "Caracterización de nuevos mediadores y marcadores de daño renal identificados mediante transcriptómica". Investigador Principal Dr. A. Ortiz Arduán.

Financiación Privada 4390/007


17. "Utilización de nanomedicinas poliméricas en el tratamiento del daño renal agudo y crónico por inhibidores de calcineurina y toxinas bacterianas". Investigador Principal Dr. M.A Ramos Cortassa.

Proyecto Público Competitivo PI11/02242.


18. "Modulación de la repuesta TH17 como nueva aproximación terapéutica en la enfermedad renal crónica y en las complicaciones asociadas a la diálisis peritoneal". Investigadora Principal Dra. M. Ruiz Ortega.

Proyecto Público Competitivo PI11/01854.


19. "Study of the new cell death pathway necroptosis in renal injury regulation and therapeutic approach" Proyecto asociado a contratos de investigadores en el SNS Miguel Servet. ". Investigadora Principal Dra. A.B Sanz Bartolomé.

Proyecto Público Competitivo CP12/03262.


Clinical trials and Observationa studies (2013)

1. Clinical trial: "Efectos de paricalcitol sobre la albuminuria, la inflamación y la fibrosis en pacientes con enfermedad renal proteinúrica crónica (Estudio Palife): Ensayo controlado randomizado". (NºEUDRACT: 2011-002877-46 Clinical trial Fase IV Multicéntrico). Investigadores Principales: S. Alexandru y J. Egido de los Ríos.


2. Clinical trial "Estudio de Bardoxolona metilo en pacientes con enfermedad renal crónica y diabetes tipo 2: Aparición de episodios renales (BEACON)" (NºEUDRACT: 2010-022297-14 Clinical trial Fase III Multicéntrico Internacional). Investigador Principal: J. Egido de los Ríos.


3. Clinical trial "Tratamiento intervencionista aleatorizado, doble ciego, de asignación de grupo único, controlado con placebo para evaluar la eficacia y seguridad de dos dosis diferentes de Nefecon ® en pacientes con nefropatía IGA primaria en riesgo de desarrollar la etapa final de enfermedad renal" (NºEUDRACT: 2012-001923-11. Clinical trial Fase II Multicéntrico Internacional). Investigador Principal: J. Egido de los Ríos.


4. Clinical trial "Estudio aleatorizado, doble ciego con dosis paralelas de Fresolimumab o placebo en pacientes con glomeruloesclerosis focal y segmentaria primaria resistente a esteroides" (NºEUDRACT: 2012-002365-35. Clinical trial Fase II Multicéntrico Internacional). Investigador Principal: J. Egido de los Ríos.


5. Clinical trial "Estudio aleatorizado, doble ciego con grupos paralelos y controlado con placebo del efecto de Atrasetan sobre los resultados renales de sujetos con diabetes tipo 2 y nefropatía sonar: ensayo de nefropagía diabética con Atrasetán". (NºEUDRACT: 2012-005848-21. Clinical trial Fase III Multicéntrico Internacional. Investigador Principal: J. Egido de los Ríos.


6. Clinical trial "Estudio de dosis múltiples, con dos grupos, control activo, doble ciego y doble enmascarado para comparar la eficacia y la seguridad terapéutica de dosis orales de Cinacalcet HCI con dosis intravenosas de AMG 416 en sujetos sometidos a hemodiálisis con hiperparatiroidismo secundario". (NºEUDRACT: 2013-000192-33. Clinical trial Fase III Multicéntrico Internacional. Investigador Principal: J. E. González Parra.


7. Clinical trial "Evaluación de la utilidad del alpurinol en la prevención de la morbilidad cardiovascular de los pacientes con enfermedad renal crónica (ERC) e hiperuricemia". (NºEUDRACT: 2007-006994-10. Clinical trial Fase IV Multicéntrico). Investigador Principal: A. Ortiz Arduán.


8. Clinical trial "Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de BIIB023 en sujetos con nefritis lúpica". (NºEUDRACT: 2011-002159-32. Clinical trial Fase II Multicéntrico Internacional). Investigador Principal: A. Ortiz Arduán.


9. Clinical trial aleatorizado para evaluar la efectividad de un programa de intervención multimodal en pacientes diabéticos tipo 2 prefrágiles y frágiles sobre la fragilidad y la calidad de vida: estudio MID-Frail". Clinical trial Multicéntrico Internacional). Investigadora Principal: A. Rovira.


10. Clinical trial "Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de Canaglifocina comparada con placebo en el tratamiento de sujetos mayores con diabetes mellitus II y control glucémico insuficiente". (NºEUDRACT: 2010-018411-15. Clinical trial Fase III Multicéntrico Internacional). Investigadora Principal: A. Rovira.


11. Clinical trial "TECOS: Ensayo aleatorizado y controlado con placebo para evaluar los sucesos cardiovasculares tras el tratamiento con Sitagliptina en pacientes con diabetes mellitus II y control glucémico inadecuado con monoterapia o biterapia antidiabética". (NºEUDRACT: 2008-006719-20. Clinical trial Fase III Multicéntrico Internacional). Investigadora Principal: A. Rovira.


12. Clinical trial "Ensayo aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de la Taspoglutida (RO5073031) sobre los resultados cardiovasculares en sujetos con diabetes de tipo 2 mal controlada y enfermedad cardiovascular documentada". (NºEUDRACT: 2009-014986-22. Clinical trial Fase III Multicéntrico Internacional). Investigador Principal: C. Iborra Cuevas.


13. Observational studies "Estudio español retrospectivo y observacional para determinar el tiempo transcurrido hasta alcanzar la normalización hormonal según la dosis e intervalos de administración de Somatulina autogel comúnmente utilizados en la práctica clínica habitual del tratamiento de pacientes acromegálicos". Ref. 5520/001 Investigadora Principal: M. A. Gonzalo Redondo.


14. Observational studies "Registro europeo multinacional sobre la prevención de episodios tromboembólicos en fibrilación auricular". Ref. 27146/001. Investigadora Principal: M.D. Joya Seijo.


15. Observational studies "Iniciativa para la evolución clínica de los pacientes en diálisis". Ref. 4390/006. Investigador Principal: A. Ortiz Arduán.


16. Observational studies "Evaluación de la frecuencia de la hiperglucemia postprandial en paciente con diabetes mellitus tipo 2, tratados con insulina basal, con los valores de glucosa en ayunas controlados y con un control no adecuado de los valores de hemoglobina glicada (HbA1c)". Ref. EO 88/2012. Investigadora Principal: A. Rovira Loscos.


Patents

P201330663 "Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano"


P201430081 "Composición farmacéutica y uso para la fabricación de un medicamento para el tratamiento de la enfermedad renal crónica y método de selección de compuestos"


P201430796 "Péptido derivado de Socs1 para su uso en complicaciones crónicas de la diabetes"